A randomized and parallel controlled trial design of comparing the new treatment group of Roxadustat combined with Sacubitril Valsartan Sodium Tablets with the traditional treatment group of recombinant human erythropoietin (EPO) combined with ACEI or ARB in Chinese patients with cardiorenal anemia syndrome.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
40
Select the appropriate dose according to the patient's situation
Select the appropriate ACEI /ARB according to the subject's situation or follow its previous medication
Department of Nephrology, Affiliated Hospital of Qingdao University
Qingdao, Shangdong, China
RECRUITINGChanges of hemoglobin level before and after treatment
By detecting blood routine,calculate the changes of hemoglobin.Change value of hemoglobin level(g/L) = baseline hemoglobin level(g/L) - hemoglobin level after treatment(g/L)
Time frame: Day0-Day90
Changes of ejection fraction before and after treatment
Cardiac ejection fraction was measured by cardiac ultrasound before and after treatment，and change of cardiac ejection fraction(%) = baseline cardiac ejection fraction level(%) - post-treatment cardiac ejection fraction level(%)
Time frame: Day0-Day90
Incidence of acute heart failure, acute myocardial infarction, severe hyperkalemia and severe anemia during treatment
Incidence rate = number of patients with the events/ total number of patients included in the study in this group.
Time frame: Day0-Day90
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.